🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

18 recruiting trials

for Extrahepatic Cholangiocarcinoma

Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma NCT07780838Phase 21 site📍 Columbus Ohio State University Comprehensive Cancer Center · Tests: Biospecimen Collection, Cisplatin, Computed Tomography, Durvalumab, Gemcitabine Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer NCT07614061Phase 11 site📍 Shanghai Shanghai Zhongshan Hospital · Tests: BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors NCT07334119Phase 17 sites📍 Darlinghurst📍 Randwick📍 Waratah Myeloid Therapeutics · Tests: MT-304, MT-304 + Nivolumab Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study NCT06964425NA1 site📍 Olomouc University Hospital Olomouc · Tests: Endoscopic retrograde cholangiopancreatography (ERCP) Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277NA1 site📍 Sacramento University of California, Davis · Tests: Ablative local therapy Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma NCT06440993Phase 212 sites📍 Aachen📍 Bonn📍 Cologne Institut für Klinische Krebsforschung IKF GmbH at Krankenha… · Tests: Gemcitabine, Cisplatin, Durvalumab, ID-RFA Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma NCT06168292NA1 site📍 Goyang-si National Cancer Center, Korea · Tests: ID-RFA and Radiotherapy A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer NCT07265674Phase 318 sites📍 Duarte📍 Orange📍 Santa Monica J-Pharma Co., Ltd. · Tests: Nanvuranlat, Physician's Best Choice Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study NCT07636824Phase 21 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… · Tests: Postoperative radiotherapy, Capecitabine or S-1 Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer NCT06274879Phase 24 sites📍 Bern📍 Geneva📍 Lucerne Insel Gruppe AG, University Hospital Bern · Tests: Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography … A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening NCT07176962n/a1 site📍 Shanghai Yingbin Liu, MD, PhD, FACS Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer NCT06282575Phase 3185 sites📍 Duarte📍 Lone Tree📍 Orlando Jazz Pharmaceuticals · Tests: Zanidatamab, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels NCT07282912Phase 21 site📍 New Haven Yale University · Tests: Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test Repeated Endobiliary Radiofrequency Ablation Plus Durvalumab, Gemcitabine, and Cisplatin for Unresectable Extrahepatic Cholangiocarcinoma NCT07235007NA8 sites📍 Aichi📍 Aichi📍 Aichi Aichi Medical University · Tests: Endobiliary Radiofrequency Ablation (EB-RFA), Plastic Biliary Stent Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer NCT07641036Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-HC01 dual-target CARNK cells, Fludarabine, Cyclophosphamide Cosiporfin Sodium for Injection Photodynamic Therapy NCT07398339Phase 21 site📍 Shanghai Shanghai Guangsheng Biopharmaceutical Co., Ltd · Tests: Cosiporfin Sodium for injection, DVDMS, Gemcitabine Hydrochloride for Injection, Cisplatin for injection Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma NCT06923475Phase 2, Phase 31 site📍 Amsterdam Amsterdam UMC, location VUmc · Tests: Pembrolizumab, Gemcitabine, Cisplatin Bile Omics for Diagnosing Indeterminate Biliary Strictures NCT07007832n/a1 site📍 Shanghai Shanghai General Hospital, Shanghai Jiao Tong University Sc… · Tests: Endoscopic retrograde cholangiopancreatography
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy